Navigation Links
Thyroid hormone analogue for treating high cholesterol
Date:3/11/2010

MANHASSET, NY An experimental thyroid drug reduces cholesterol without the troublesome side effects experienced by some people on statins, according to a study published today in The New England Journal of Medicine. An international team of investigators at Johns Hopkins Medical Institutions, the Karolinska University Hospital and Institute, and The Feinstein Institute for Medical Research tested a substance called Eprotirome in patients with high cholesterol.

Following 189 people with high cholesterol over a three-month period, they observed that it lowered cholesterol levels without the classic thyroid risks to the heart and bone, The study was supported by Karo Bio in Sweden, a company that is developing the drug for its cholesterol-lowering effects.

Over three decades, Irwin Klein, MD, an endocrinologist at the Feinstein Institute, has been at the forefront of researching the connection between thyroid and heart health. It seemed that people with underactive thyroid glands also had high cholesterol levels. These high cholesterol levels were dramatically reduced with thyroid hormone replacement. But the problem in using thyroid hormone for cholesterol lowering is the side effects of an overactive thyroid gland: people can become anxious and have heart palpitations, muscle weakness and bone thinning.

Scientists spent years trying to develop thyroid analogs that lowered lipids without unwanted side effects. American scientists, including Dr. Klein and John D. Baxter, MD, a senior member of The Methodist Hospital Research Institute, have been working with Karo Bio scientists to solve this problem. They landed on one in particular that lowered cholesterol without any of the problems with the traditional thyroid medicines. Phase I studies showed the drug safe.

In the current Phase II study, they reported that it was both safe and effective in lowering cholesterol. What is not known from this study is whether this lowering of cholesterol will ultimately protect patients from heart disease. Dr. Klein said he thinks it may work to reduce cardiovascular disease. "Every percentage that you lower cholesterol, you lower the risk for heart disease," he said. "High cholesterol is the single most modifiable risk factor." About one in three people have cholesterol levels that are higher than the national guidelines set by federal agencies.

Jens Kristensen, a scientist at Karo Bio and the lead author on the study, and his colleagues also found that the experimental medicine lowered a cholesterol product in the blood called lipoprotein A, which is damaging to the heart. There are no available medicines that lower lipoprotein A and Eprotirome lowered the levels by 33 percent.

Since cholesterol lowering is a surrogate marker for heart disease, the scientists will have to conduct other studies to test whether it does in fact reduce heart disease. The next phase of testing must include larger numbers of patients. If the results hold, it could ultimately be used as an alternative to statins. A small percentage of patients can't take statins, either because they don't work to lower cholesterol for them or they suffer from unrelenting side effects such as muscle pains, myopathy and tiredness.


'/>"/>

Contact: Jamie Talan
jtalan@nshs.edu
516-562-1232
North Shore-Long Island Jewish (LIJ) Health System
Source:Eurekalert

Related medicine news :

1. Thyroid Hormone Analogue for Treating High Cholesterol
2. Thyroid Disease: The Hidden Epidemic
3. No End In Sight To The Armour Thyroid Shortage?
4. Stain repellent chemical linked to thyroid disease in adults
5. It's January...Do You Know Where Your Thyroid Is? Thyroid Awareness Month Focuses on Millions of Undiagnosed Americans with Thyroid Problems
6. Low Thyroid Levels May Up Need for Assisted Delivery
7. Pregnancy Complication May Be Linked to Thyroid Problems
8. Thyroid Cancer Higher in Volcanic Areas
9. Newly revised guidelines for managing thyroid cancer published in Thyroid journal
10. Thyroid surgery safe for older patients, study finds
11. Studies Evaluate Thyroid Treatment During Pregnancy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Comfort Keepers® of ... Cancer Society and the Road To Recovery® program to drive cancer patients to and ... other adults to ensure the highest quality of life and ongoing independence. Getting ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
Breaking Medicine Technology: